Action
Tirofiban is a synthetic, nonpeptide inhibitor acting at glycoprotein-(GP)-receptors, type IIb/IIIa, in human thrombocytes. It therefore constitutes an anticoagulant, specifically an inhibitor of thrombocyte aggregation. Tirofiban is initially given as rapid intravenous infusion at a rate of 0.4 µg/kg and minute for 30 minutes. Upon completion of the initial infusion, the rate is decreased to 0.1 µg/kg and minute delivered as continuous infusion

Status

Trial(s)
  = Ongoing
  = Completed

	SaTIS	Safety of Tirofiban in Acute Ischemic Stroke
	SETIS	Study of Efficacy of Tirofiban in Acute Ishemic Stroke

UID: 251